Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
350
resultados
Última actualización
22/10/2026 [11:01:00]
Resumen de: EP4826385A1
The present invention relates to method of determining risk of an inflammatory condition, and/or risk of progression of an inflammatory condition, as well as to compounds for use in these methods.
Resumen de: WO2025016362A1
The present invention relates to the field of biomedicine, in particular, to the use of an intracerebral phosphate homeostasis promoter in cerebral calcification diseases. The intracerebral phosphate homeostasis promoter comprises an agent capable of regulating alternative splicing in an intron of the SLC20A2 gene or an agent targeting astrocytes. In addition, further provided in the present invention are an agent capable of regulating alternative splicing in an intron of the SLC20A2 gene, and the use thereof. Further provided in the present invention are a cerebral calcification model based on alternative splicing in an intron of the human SLC20A2 gene, and a preparation method therefor and the use thereof.
Resumen de: WO2022182949A2
The present disclosure provides biomarkers associated with caveolin-1 peptide therapy in subjects with interstitial lung disease. In particular, the present disclosure describes biomarkers such as MYDGF, soluble RAGE, pSMAD2/3, and PDGFRβ associated with caveolin-1 peptide therapy in subjects with idiopathic pulmonary fibrosis. These biomarkers could be used to determine efficacy, monitoring, and optimal dosing of caveolin-1 peptide therapy in subjects with interstitial lung disease.
Resumen de: US20260318926A1
The present invention refers to the use of a biomarker for measuring the efficacy or effectiveness of treatments for neurodegenerative diseases, in particular, for Alzheimer's disease.
Resumen de: WO2026217919A1
Various examples are provided related to monitoring at least one chemical analyte, biological analyte, or combinations thereof in the nasal cavity. In one example, a process includes receiving an output signal from an electrochemical sensor, applying a trained machine learning model or algorithm to the output signal to detect a presence of at least one analyte in the nasal cavity, and determining, in response to the detected presence, an identity or amount of the analyte. In another example, a process includes receiving an output signal from an electrode implanted in the nasal cavity, applying a trained machine learning model or algorithm to the output signal to determine a neurochemical analyte. The information can be displayed to indicate a corresponding neurochemical level in the nasal cavity of a subject.
Resumen de: US20260317434A1
The present invention relates to antibodies or antigen-binding fragments thereof with binding specificity for interleukin-1 receptor accessory protein (IL1RAP). Furthermore, it relates to a polynucleotide encoding said antibodies, a vector comprising said polynucleotide and a recombinant host cell comprising said polynucleotide or said vector. Further, it relates to a method for producing said antibodies or antigen-binding fragments. Further, it relates to a composition comprising said antibodies or antigen-binding fragments, said polynucleotide, said vector and/or said host cell. Further, it relates to said antibodies or antigen-binding fragments, said polynucleotide, said vector, said host cell and/or said composition for use in medicine and/or for use in the prevention and/or treatment and/or alleviation and/or detection and/or diagnosis of a disease or disorder susceptible to treatment with an inhibitor of IL-1α, IL-1β, IL-33, IL-36α, IL-36β and/or IL-36γ signaling, optionally wherein the disease or disorder is associated with cells expressing IL1RAP.
Resumen de: AU2026237984A1
The present invention relates to the field of stem cell biology, in particular the linage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hESC), human induced pluripotent stem cells (hiPSC), somatic stem cells, cancer stem cells, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hESC and/or hiPSC to nociceptors (i.e. nociceptor cells) using novel culture conditions. The nociceptors made using the methods of the present invention are further contemplated for various uses including, but limited to, use in in vitro drug discovery assays, pain research, and as a therapeutic to reverse disease of, or damage to, the peripheral nervous system (PNS). Further, compositions and methods are provided for producing melanocytes from human pluripotent stem cells for use in disease modeling. ep e p
Resumen de: US20260317373A1
The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. For example, the peptides may be administered to subjects in need of a mitochondrial-targeted antioxidant.
Resumen de: US20260318900A1
0000 Disclosed are methods for full morphological labeling of individual neurons from any species or cell type for subsequent cell-delineated protein analysis. These methods, which combines patch-clamp electrophysiology with epitope-preserving magnified analysis of proteome (eMAP), additionally allow for correlation of physiological properties with subcellular protein expression.
Resumen de: US20260315577A1
0000 The present disclosure relates to compositions and methods useful for assessing the hemostatic efficacy in a patient having suffered from intracranial hemorrhage while undergoing an anticoagulation treatment with a factor Xa (fXa) inhibitor. The method can include administering to the patient a fXa derivative that has reduced catalytic activity as compared to the wild-type fXa protein, is capable of binding to the factor Xa inhibitor and cannot assemble into a prothrombinase complex; obtaining a blood sample from the patient following the administration; and measuring an anti-fXa activity in the sample, wherein the anti-fXa activity reflects the hemostatic efficacy in the patient. Once the assessment is made, suitable medical interventions can be implemented.
Resumen de: WO2026216120A1
The present disclosure can provide a simple and accurate method for quantifying ergothioneine in a sample containing globin protein. The present disclosure provides a method for quantifying ergothioneine in a collected sample, the method including: (A) a step for heating the sample; (B) a step for mixing the heated sample with trichloroacetic acid; and (C) a step for subjecting the sample obtained in step (B) to a quantification operation.
Resumen de: AU2025231883A1
Blood-based biomarkers involving evaluation of membrane protein clustering (MPC) on peripherally circulating lymphocytes can identify individuals experiencing depression, schizophrenia, or bipolar disorder, while differentiating those that will respond to treatment from those that will not respond to treatment within the depressed populations. These markers can help diagnose and treat depression, schizophrenia, or bipolar disorder. Further, this diagnostic tool can identify individuals with treatment-resistant depression earlier. The disclosed automated method improves the throughput of blood-based biomarkers and can be standardized across multiple sites of blood collection/analysis. The automated approach performs similarly to human scorers for each method of blood smear collection in accurately obtaining cluster size means for each sample.
Resumen de: AU2025231935A1
Provided herein are methods for providing personalized antioxidant supplement blend for an individual subject based on the levels of antioxidant biomarkers, prooxidant biomarkers, and genetic statuses. The antioxidant supplement blend includes suggestions for one or more of diet, supplements, and/or life style changes for the individual.
Resumen de: AU2025249144A1
The present disclosure relates in some aspects to methods of labeling a detection reagent and uses thereof for detecting and diagnosing types of amyloid-related diseases. Also provided herein are methods of treatment comprising selecting a treatment based upon a particular type of amyloid disease.
Resumen de: AU2025232447A1
The present invention relates to methods and products for assessing autophagic flux, and more specifically provides a biochemical functional measure used to quantify autophagic flux in sub-populations of blood cells. The present invention also provides lysosomal system markers for use in the methods described herein, systems for assessing autophagic flux, methods of identifying markers indicative of autophagic flux, and methods of treating subjects found to be suffering from, or susceptible to, a disease, condition or state associated with autophagic flux dysfunction using the methods described herein.
Resumen de: US20260317833A1
Methods and systems for detecting disease using personalized synthetic biomarkers. Subject-specific molecular data, including one or more of genomic, epigenomic, transcriptomic, proteomic, or metabolomic data, are analyzed to identify disease-associated biological activities. Based on these activities, a set of synthetic biomarkers is designed for the subject, wherein each biomarker is configured to generate a detectable signal in response to a target biological process. The synthetic biomarkers are administered to the subject or contacted with a biological sample, and resulting signals are detected using analytical assays. Detection of the signals enables identification, monitoring, or assessment of disease presence, progression, or recurrence. In certain embodiments, the methods are applied to cancer, including minimal residual disease (MRD) detection, and may incorporate longitudinal monitoring and adaptive updating of biomarker panels based on changes in subject-specific molecular profiles.
Resumen de: US20260318925A1
Methods are disclosed that comprise providing a biological sample comprising extracellular vesicles, wherein the biological sample further comprises at least one extracellular vesicle biomarker and at least one cytosolic protein, cytokine, or secreted disease biomarker; contacting a solid support comprising capture agents associated therewith with the biological sample under conditions wherein the capture agents selectively bind to the at least one extracellular biomarker on the vesicles, thereby capturing said vesicles having the at least one extracellular vesicle biomarker on the solid support; separating the solid support from the biological sample; detecting a level of the at least one cytosolic protein, cytokine or secreted disease biomarker on the vesicles captured on the solid support using a detection agent that selectively binds to the at least one cytosolic protein, cytokine or secreted disease biomarker, wherein the vesicles are not lysed or permeabilized; detecting a level of the at least one extracellular vesicle biomarker on the vesicles; and determining a level of risk or presence of a neurological disorder or neurodegenerative disease based on the level of the at least one cytosolic protein, cytokine, or secreted disease biomarker in relation to the level of the at least one extracellular vesicle biomarker.
Resumen de: US20260321424A1
Techniques for identifying a health-related condition based on a protein-based analysis, and optionally based on a nucleic acid sequencing-based analysis are described. In an example method, protein data of a sample obtained from the subject is identified. The sequence read data is indicative of proteins in the sample. The example method further comprises determining a protein score based on the protein data, and determining, based on the protein score, whether to determine a genomic score indicative of sequences of nucleic acid molecules in the sample. In the example method, input features are generated based on the protein score and/or the genomic score and classifying, using a classifier, the health-related condition of the subject based on the input features.
Resumen de: WO2026217989A1
Provided herein are methods of treating a subject having benign prostatic hyperplasia that include, for example, identifying a subject having a white blood cell that has an elevated level of methylation of SRD5A2 as compared to a reference level; and administering to the identified subject a first therapy such as a combination therapy comprising a therapeutically effective amount of a 5-alpha reductase inhibitor and a stroma-niched signaling therapeutic.
Resumen de: US20260318911A1
0000 A lateral flow assay device for detecting the presence of, or quantifying an amount or concentration of, analyte in a sample. The device includes (1) a conjugate region including a binding reagent coupled to a signal-generating particle, wherein the binding reagent comprises a first antibody configured to bind lipopolysaccharide, and wherein the binding reagent is mobile relative to the device, and (2) an analytical membrane in fluid communication with the conjugate region, the analytical membrane comprising a test region and a control region. The test region includes an immobilized capture reagent configured to capture a complex including the analyte and the binding reagent, wherein the immobilized capture reagent is a second antibody. The control region includes a control component configured to capture the binding reagent coupled to the signal-generating particle.
Resumen de: WO2026218003A2
Provided are methods and compositions related to toxicity associated with administration of cell therapy for the treatment of diseases or conditions, e.g., cancer, including methods for use in predicting and treating toxicity. In some embodiments, the toxicity is a neurotoxicity or cytokine release syndrome (CRS), such as severe neurotoxicity or severe CRS. The methods generally involve determining a biosignature comprising of a differential modulation of one or more protein-interactions in a CAR-T cell to be administered relative to a reference standard. In some embodiments, the methods further involve administering an agent or therapy for treating, ameliorating, preventing, delaying and/or attenuating the development of the toxicity, such as neurotoxicity or CRS, such as severe neurotoxicity or severe CRS.
Resumen de: US20260317734A1
0000 Many embodiments are directed to systems, compositions, and methods to control the ISR. Numerous embodiments utilize optogenetic control to control the ISR. Optogenetic control can be provided by an engineered ISR kinase that can dynamically stimulate the ISR pathway. Using optogenetic control, many embodiments enable the selective activation of a single kinase of the ISR pathway without inducing real molecular damage, greatly reducing the combinatorial complexity of the signals that are turned on by real stressors. By changing the intensity of light stimulation, various embodiments can tune the fraction of optogenetic proteins in the activated state, thereby precisely altering the perceived intensity. Additionally, precisely defined input dynamics can be delivered by toggling lights between on and off positions. Many embodiments are scalable and/or capable of high-throughput delivery, allowing for precise dissections of the ISR pathway.
Resumen de: EP4822355A2
0001 Disclosed herein are methods based on the identification of reduced Hsp70 levels in PBMC samples serving as a biomarker for diseases presenting with a reduced level of Hsp70, such as lysosomal storage diseases, neurodegenerative diseases and muscular diseases.
Resumen de: EP4821941A1
The present invention provides a cerebrum-targeting peptide including an amino acid sequence represented by SEQ ID NO: 1, and a method for screening a peptide that binds to a target cell in a non-human organism, comprising contacting a peptide library consisting of 7-amino acid peptides with a target cell to recover a group of peptides that bind to the target cell to obtain a peptide population that binds to the target cell, and selecting, from the peptide population, a peptide consisting of an amino acid sequence that is identical to a portion of a protein expressed in the non-human organism and that is also identical to a portion of a protein constituting a virus, as a peptide that binds to the target cell.
Nº publicación: EP4819918A1 14/10/2026
Solicitante:
ROCKET SCIENCE HEALTH CORP [CA]
Rocket Science Health Corp.
Resumen de: WO2025118073A1
The present disclosure describes formulations, methods, and devices for biomarker sampling and therapeutic delivery using magnetic formulations. When combined with the application of external magnetic fields, magnetic formulations move within the nasal cavity. Magnetic formulations provide benefits including the ability to: target or steer placement of the formulations via a magnetic field, enhance mixing of the formulation via a magnetic field, enhance biological material collection via antibody-coated magnetic beads, or enhance sample retrieval via a magnetic-tipped inserter. Example biological materials for collection include proteins, enzymes, neural stem cells, and other biomarkers.
BOPI
Sede Electrónica
